UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Alu elements mediate MYB gene tandem duplication in human T-ALL

The Journal of experimental medicine, 2007-12, Vol.204 (13), p.3059-3066

2007

Volltextzugriff (PDF)

Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7048-7048

2013

Volltextzugriff (PDF)

Clinical JAK2 V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations

American journal of hematology, 2008-06, Vol.83 (6), p.519-520

2008

Volltextzugriff (PDF)

Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations

American journal of hematology, 2008-06, Vol.83 (6), p.519-520

2008

Volltextzugriff (PDF)

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Blood, 2012-11, Vol.120 (21), p.915-915

2012

Volltextzugriff (PDF)

Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols

Journal of clinical oncology, 2007-03, Vol.25 (7), p.813-819

2007

Volltextzugriff (PDF)

In Vivo administration of dichloroacetic acid suppresses spontaneous apoptosis in murine hepatocytes

Cancer research (Chicago, Ill.), 1995-09, Vol.55 (17), p.3702-3705

1995

Volltextzugriff (PDF)

JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations

Blood, 2007-11, Vol.110 (11), p.1634-1634

2007

Volltextzugriff (PDF)

Leverage and Dividend Irrelevancy Under Corporate and Personal Taxation

The Journal of finance (New York), 1980-05, Vol.35 (2), p.453-464

1980

Volltextzugriff (PDF)

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Blood, 2012-11, Vol.120 (21), p.3747-3747

2012

Volltextzugriff (PDF)

Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay

Cold Spring Harbor molecular case studies, 2015-10, Vol.1 (1), p.a000307-a000307

2015

Volltextzugriff (PDF)

Optimal capital structure under corporate and personal taxation

Journal of financial economics, 1980-03, Vol.8 (1), p.3-29

1980

Volltextzugriff (PDF)

PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation

Clinical lymphoma, myeloma and leukemia, 2013-09, Vol.13, p.S384-S384

2013

Volltextzugriff (PDF)

PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.6503-6503

2012

Volltextzugriff (PDF)

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Blood, 2006-12, Vol.108 (12), p.3674-3681

2006

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(9)
Science & Technology
(9)
Humans
(6)
Male
(6)
Female
(5)
Adult
(4)
Biological And Medical Sciences
(4)
Hematology
(4)
Medical Sciences
(4)
Middle Aged
(4)
Hematologic And Hematopoietic Diseases
(3)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(3)
Oncology
(3)
Adolescent
(2)
Age Factors
(2)
Aged
(2)
Aged, 80 And Over
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Business Finance
(2)
Chemotherapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alu elements mediate MYB gene tandem duplication in human T-ALL

Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Clinical JAK2 V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations

Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols

In Vivo administration of dichloroacetic acid suppresses spontaneous apoptosis in murine hepatocytes

JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations

Leverage and Dividend Irrelevancy Under Corporate and Personal Taxation

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay

Optimal capital structure under corporate and personal taxation

PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation

PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Suchergebnisse filtern